Low dose Amantadine and Escitalopram combination in Atypical Parkinsonian disorders- A Retrospective chart review

Introduction The response to conventional antiparkinsonian medications is elusive in atypical parkinsonian disorders. Improvement symptoms disorders has been reported with anecdotal use of Amantadine. role serotonergic control over the nigrostriatal pathway led Escitalopram. Objectives To examine efficacy low dose Amantadine and Escitalopram combination treatment disorder Methods A retrospective chart review Atypical Parkinsonian patients who received had follow up assessment available for a minimum four months were studied. primary outcome measure was change Progressive Supranuclear Palsy rating scale, Unified Multiple System Atrophy scale score Clinical Global Scale Change visits. Results total 8 mean age 68.5 years, 6 diagnosis Palsy(PSP) 2 Atrophy(MSA) met selection criteria study. Patients treated 50mg twice daily 5mg once daily. symptom domain respond first autonomic followed by gait, mentation, limb bulbar symptoms. unique dopaminergic NMDA antagonist properties. Serotonin modulation functions circuitry. Thus, combining can help ameliorate array Conclusions PSP MSA responded as evidenced objective scales subjective clinician assessment. Further prospective trials longer duration are needed establish effect size stability response. KEYWORDS: steele richardson olszewski disease, shy dragger syndrome, antidepressants Disclosure Interest None Declared